Fleury-Hermes Pardini deal won't be further scrutinized by Brazil CADE Tribunal
Medical laboratory firm Fleury's planned acquisition of rival Hermes Pardini won't be further scrutinized by the Brazilian competition authority. The Tribunal of the Administrative Council for Economic Defense today rejected a...To view the full article, register now.
Already a subscriber? Click here to view full article